carmustine has been researched along with Blood Platelet Disorders in 2 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Blood Platelet Disorders: Disorders caused by abnormalities in platelet count or function.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Panella, TJ | 1 |
| Peters, W | 1 |
| White, JG | 1 |
| Hannun, YA | 1 |
| Greenberg, CS | 1 |
| Desser, RK | 1 |
| Ultmann, JE | 1 |
1 review available for carmustine and Blood Platelet Disorders
| Article | Year |
|---|---|
The sensitivity of Hodgkin's disease to chemotherapeutic agents administered singly.
Topics: Adrenal Cortex Hormones; Alopecia; Antineoplastic Agents; Bleomycin; Blood Platelet Disorders; Carmu | 1973 |
1 other study available for carmustine and Blood Platelet Disorders
| Article | Year |
|---|---|
Platelets acquire a secretion defect after high-dose chemotherapy.
Topics: Adenosine Triphosphate; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Platelet Disord | 1990 |